ATE303369T1 - Glucocorticoid rezeptor modulatoren - Google Patents

Glucocorticoid rezeptor modulatoren

Info

Publication number
ATE303369T1
ATE303369T1 AT01308789T AT01308789T ATE303369T1 AT E303369 T1 ATE303369 T1 AT E303369T1 AT 01308789 T AT01308789 T AT 01308789T AT 01308789 T AT01308789 T AT 01308789T AT E303369 T1 ATE303369 T1 AT E303369T1
Authority
AT
Austria
Prior art keywords
glucocorticoid receptor
compounds
present
receptor modulators
provides
Prior art date
Application number
AT01308789T
Other languages
English (en)
Inventor
Kevin Kun Liu
Bradley P Morgan
Ralph Pelton Robinson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE303369T1 publication Critical patent/ATE303369T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT01308789T 2000-10-30 2001-10-16 Glucocorticoid rezeptor modulatoren ATE303369T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24430200P 2000-10-30 2000-10-30

Publications (1)

Publication Number Publication Date
ATE303369T1 true ATE303369T1 (de) 2005-09-15

Family

ID=22922191

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01308789T ATE303369T1 (de) 2000-10-30 2001-10-16 Glucocorticoid rezeptor modulatoren

Country Status (9)

Country Link
US (1) US6852719B2 (de)
EP (1) EP1201660B1 (de)
JP (1) JP2002193955A (de)
AT (1) ATE303369T1 (de)
BR (1) BR0104834A (de)
CA (1) CA2360313C (de)
DE (1) DE60113032T2 (de)
ES (1) ES2246292T3 (de)
MX (1) MXPA01011108A (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL180679A0 (en) * 2000-10-27 2009-02-11 Pfizer Prod Inc Process for the preparation of non-steroidal glucocorticoid receptor modulators
WO2004009017A2 (en) * 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
AU2003299311A1 (en) * 2002-12-18 2004-07-09 University Of Zurich Treatment of neuro-psychiatric disorders
US7625921B2 (en) * 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP4958774B2 (ja) * 2004-07-02 2012-06-20 コーセプト セラピューティクス, インコーポレイテッド 改変されたピリミジン糖質コルチコイドレセプター調節因子
US20060154981A1 (en) * 2005-01-12 2006-07-13 Alcon, Inc. Method of reducing intraocular pressure and treating glaucoma
CA2594943A1 (en) * 2005-01-19 2006-07-27 Merck & Co., Inc. Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
AU2006206654A1 (en) * 2005-01-19 2006-07-27 Merck & Co., Inc. Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of Alzheimer's disease
EP1944290B1 (de) * 2005-09-14 2013-12-04 Santen Pharmaceutical Co., Ltd. Neues 1,2-dihydrochinolinderivat mit glucocorticoidrezeptorbindender aktivität
SI1995242T1 (sl) 2006-03-14 2013-01-31 Santen Pharmaceutical Co., Ltd. Nov derivat 1,2,3,4-tetrahidrokinoksalina z aktivnostjo vezanja glukokortikoidnega receptorja
PL2085387T3 (pl) 2006-11-14 2013-09-30 Ayumi Pharmaceutical Corp Nowe pochodne 1,2-dihydrochinoliny zawierające jako podstawniki fenylochalkogeno-podstawioną niższą grupę alkilową oraz wprowadzoną przez ester grupę fenylową
TWI410422B (zh) 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
WO2008093227A1 (en) * 2007-02-02 2008-08-07 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
CA2687948A1 (en) 2007-05-29 2008-12-04 Mamoru Matsuda Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein andhas glucocorticoid receptor-binding activity
KR20110010634A (ko) 2008-05-12 2011-02-01 산텐 세이야꾸 가부시키가이샤 치환 옥시기를 가지는 2,2,4-트리메틸-6-페닐-1,2-디하이드로퀴놀린 유도체를 포함하는 글루코코르티코이드 수용체 작용제
ES2527137T3 (es) 2008-07-28 2015-01-21 Pfizer Inc. Compuestos de fenantrenona, composiciones y procedimientos
EA018420B1 (ru) 2008-09-12 2013-07-30 Сантен Фармасьютикал Ко., Лтд. Агонист глюкокортикоидного рецептора, содержащий новые производные 1,2,3,4-тетрагидрохиноксалина с фенильной группой, имеющей структуру эфира сульфоновой кислоты, введенной в нее в качестве заместителя
GB2477256B (en) 2008-11-07 2013-12-25 Univ Sheffield Determination of predisposition towards subclinical Cushing's syndrome or incidentaloma
CN103298343A (zh) * 2011-01-07 2013-09-11 科赛普特治疗公司 类固醇和糖皮质激素受体拮抗剂组合疗法
KR101925955B1 (ko) 2011-03-18 2018-12-06 코어셉트 쎄라퓨틱스, 잉크. 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제
TW201422590A (zh) * 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (de) 2012-12-21 2016-04-27 Abbvie Inc Heterocyclische nuklearhormonrezeptormodulatoren
EP3342768A4 (de) 2015-08-25 2019-01-23 Santen Pharmaceutical Co., Ltd. [ 4-(1, 3, 3-trimethyl-2-oxo-3, 4-dihydro-1 h-chinoxalin-7-yl) phenoxy ] ethyloxyverbindung oder salz davon
EP3768324B1 (de) 2018-03-22 2025-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur modulierung der aktivität innater lymphoider zellen, antikörper-arzneimittelkonjugate und verwendungen in der therapie
ES2987563T3 (es) 2018-06-04 2024-11-15 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides ciclohexenilo pirimidina
US11903945B2 (en) 2019-12-11 2024-02-20 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
MX2022013804A (es) 2020-05-06 2022-11-30 Corcept Therapeutics Inc Polimorfos de moduladores de los receptores de pirimidin-ciclohexil-glucocorticoides.
WO2021226258A1 (en) 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
IL303881A (en) 2020-12-21 2023-08-01 Corcept Therapeutics Inc Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
US12616698B2 (en) 2021-05-05 2026-05-05 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683091A (en) 1967-11-13 1972-08-08 Wataru Nagata Certain phenanthrene compounds for treatment of acne
JPS50111098A (de) 1974-02-18 1975-09-01
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
JPH06263688A (ja) 1991-09-04 1994-09-20 Otsuka Pharmaceut Factory Inc フェナンスレン誘導体
KR950703941A (ko) 1993-10-13 1995-11-17 오오쓰까 아끼히꼬 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor)
ATE156836T1 (de) 1994-05-19 1997-08-15 Akzo Nobel Nv 11,21-bisphenyl-19-nor-pregnan derivate
JPH0952899A (ja) 1994-09-30 1997-02-25 Tsumura & Co ロイコトリエン拮抗剤
US5696130A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
US5767113A (en) 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
FR2757400B1 (fr) 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
US5929058A (en) 1996-12-24 1999-07-27 Zymogenetics, Inc. Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes
IL122740A (en) * 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
EP0903146A1 (de) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (21-0H-60P) als ANitoglucocortikoid
ZA9811898B (en) 1997-12-29 2000-06-28 Ortho Mcneil Pharm Inc Anti-Inflammatory Compounds.
SK284689B6 (sk) 1998-02-13 2005-09-08 Abbott Laboratories Benzopyrano[3,4-f]chinolínová zlúčenina a liečivo s jej obsahom
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
IL139865A0 (en) 1998-06-08 2002-02-10 Karobio Ab A liver selective glucocorticoid antagonist and pharmaceutical compositions containing the same
DE69920717T2 (de) 1998-07-30 2005-10-06 Abbott Laboratories, Abbott Park Glucocorticoid selektive wirkstoffe
GB9816935D0 (en) 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
HK1042889B (zh) * 1999-04-30 2006-12-29 辉瑞产品公司 糖皮质激素受体调制剂

Also Published As

Publication number Publication date
US20040014741A1 (en) 2004-01-22
CA2360313A1 (en) 2002-04-30
BR0104834A (pt) 2002-08-20
EP1201660A1 (de) 2002-05-02
US6852719B2 (en) 2005-02-08
DE60113032T2 (de) 2006-07-06
ES2246292T3 (es) 2006-02-16
DE60113032D1 (de) 2005-10-06
MXPA01011108A (es) 2002-06-04
JP2002193955A (ja) 2002-07-10
CA2360313C (en) 2006-12-05
EP1201660B1 (de) 2005-08-31

Similar Documents

Publication Publication Date Title
DE60113032D1 (de) Glucocorticoid Rezeptor Modulatoren
DE60120077D1 (de) Modulatoren des Glucocorticoid-Rezeptors
AP1542A (en) Glucocorticoid receptor modulators.
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
BRPI0411699A (pt) compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
BR0313923A (pt) Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
TNSN08027A1 (en) Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use of same
BRPI0509761B8 (pt) compostos de quinolinona-carboxamida como agonistas de receptor de 5-ht4, composição farmacêutica, uso dos referidos compostos e seu processo de preparação
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
ATE445609T1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
PL1716152T3 (pl) Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
BR0115291A (pt) Derivados de 2-fenilaminoimidazolina fenil cetona substituìdos como antagonistas de ip
EA200700027A1 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
YU53100A (sh) Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora
GT200000197A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
BRPI0414643A (pt) composto, composições farmacêuticas, e, uso de um composto
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
BR9905974A (pt) Derivados de ácido aril carboxìlico e tetrazol
ATE434437T1 (de) Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties